Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer.
Cimetidine, a non-thiourea-containing H2-receptor antagonist, was studied in seven patients with duodenal ulcer.  Oral doses of 100, 200, and 300 mg were tested.  Each dose significantly inhibited basal and meal-stimulated secretion.  After 300 mg, basal acid secretion was essentially zero for at least five hours.  The meal-stimulated three-hour acid output after the 300-mg dose was reduced by 67%. Cimetidine, 300 mg, decreased meal-stimulated acid secretion significantly more than an optimal effective dose of propantheline bromide (P less than 0.05). Inhibition of meal-stimualted gastric acid secretion showed a significant relation to peak blood cimetidine concentration (r is equal to 0.76, P less than 0.01).  Cimetidine did not affect meal-stimulated gastrin release.  No toxicity was observed after serial doses given during these tests.  Cimetidine may be useful in treatment of acid-peptic diseases provided no important toxicity appears on chronic testing.
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D003864:Depression, Chemical; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000503:physiopathology*; D004435:Eating; D005750:Gastric Juice / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D006146:Guanidines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011413:Propantheline / Q000008:administration & dosage; D013997:Time Factors
D005755:Gastrins; D006146:Guanidines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D011413:Propantheline